Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.47 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | MAT2A | P31153 | 3/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6662535 | 0.88 | CYP19A1 (0.51) | CYP19A1ROCK2PIM1PIM3PTGER2 | |
| SCHEMBL28062496 | 0.88 | CYP19A1 (0.56) | CYP19A1PTGER2BIRC5CYP1A2METAP2 | |
| SCHEMBL6657580 | 0.86 | ROCK2 (0.48) | CYP19A1ROCK2PIM1PIM3CYP11B2 | |
| SCHEMBL6795783 | 0.82 | CYP19A1 (0.57) | CYP19A1ROCK2PIM1PIM3PTGER2 | |
| SCHEMBL4557834 | 0.82 | BIRC5 (0.62) | CYP19A1ROCK2PIM1PIM3BIRC5 | |
| SCHEMBL17067754 | 0.81 | ROCK1 (0.50) | CYP19A1CYP1A2CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL4232123 | 0.81 | ROCK1 (0.50) | CYP19A1CYP1A2CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL2264468 | 0.81 | MAPT (0.48) | CYP19A1ROCK2PIM1PIM3CYP11B2 | |
| SCHEMBL30364924 | 0.81 | MAPT (0.48) | CYP19A1ROCK2PIM1PIM3CYP11B2 | |
| SCHEMBL6845959 | 0.81 | CYP11B1 (0.54) | CYP19A1ROCK2PIM1PIM3CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855203-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855203-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7439363-B2 | Substituted indazoly(indoly)maleimide derivatives as kinase inhibitors | JANSSEN PARMACEUTICA N.V. (BE) | 2008-10-21 | — | — | US | disclosed |
| US-7439363-B2 | Substituted indazoly(indoly)maleimide derivatives as kinase inhibitors | JANSSEN PARMACEUTICA N.V. (BE) | 2008-10-21 | — | — | US | disclosed |
| EP-1654255-B1 | SUBSTITUTED INDAZOLYL(INDOLYL)MALEIMIDE DERIVATIVES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-27 | — | — | EP | disclosed |
| US-20080096949-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096949-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. | 2008-04-24 | — | — | US | disclosed |
| WO-2005000836-A1 | SUBSTITUTED INDAZOLYL(INDOLYL)MALEIMIDE DERIVATIVES AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096949-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | MAP2K2, MAP3K20, MAP2K3 | CYP19A1 3023/4885ROCK2 440/4885PIM1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.